Application to Change Lipitor Patent Accepted by Patent Office

An obstacle has been cleared for Pfizer’s best-selling cholesterol drug Lipitor because the U.S. Patent and Trademark Office has accepted the company’s application to correct a technical defect in one of the patents for the drug. The ’995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor, expires in June 2011, including the six-month pediatric exclusivity period.
Generic Line